Catalyst Biosciences, Inc. - CBIO STOCK NEWS

Catalyst Biosciences, Inc. (NASDAQ: CBIO) announced a poster presentation on Marzeptacog alfa (activated) or MarzAA at the 62nd Annual American Society of Hematology meeting, scheduled for December 5-8, 2020. The presentation will cover the Phase 3 Crimson 1 Study, which evaluates MarzAA for treating bleeding episodes in patients with Hemophilia A and B with inhibitors. The first patient is set to be dosed by late 2020. MarzAA represents the only subcutaneous bypass agent in development for these conditions. Catalyst focuses on rare hematologic disorders, with multiple clinical programs underway.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) reported its third-quarter results for 2020, ending September 30. The net loss was $16 million, equating to ($0.73) per share, an improvement from a loss of $12.7 million or ($1.06) per share in Q3 2019. The company is advancing clinical trials for its MarzAA product and expects to enroll patients in a Phase 3 study for hemophilia treatment by year-end. Cash and investments totaled $104.1 million. Additionally, Catalyst secured a patent for its complement program, providing protection until at least 2038.

Catalyst Biosciences (NASDAQ: CBIO) announced its participation in the Stifel 2020 Virtual Healthcare Conference, scheduled for November 17, 2020, at 11:20 am ET. Presenters include CEO Nassim Usman, Ph.D., and CFO Clinton Musil. The presentation can be accessed via a webcast, and will remain available for 90 days post-event on the company’s website. Catalyst focuses on developing novel therapies for rare hematologic and complement-mediated disorders, leveraging advanced protease engineering technology.

Catalyst Biosciences has secured an extension of patent protection for CB 2782-PEG until at least 2038, enhancing its market position. The patent covers engineered proteases that target complement factor 3 (C3), with therapeutic potential for conditions like dry age-related macular degeneration (AMD). Catalyst’s partnership with Biogen for CB 2782-PEG emphasizes its clinical significance. The announcement comes alongside an emphasis on expanding clinical candidates from their protease engineering platform, underscoring ongoing innovation within the company.

Catalyst Biosciences, based in South San Francisco, announced that Dr. Grant Blouse will present at the Stifel Immunology and Inflammation Virtual Summit on October 1, 2020, at 9:00 AM ET. He will discuss the evolution of complement-targeted therapies. Interested participants can access the live presentation via a provided link, with an archived version available for 90 days post-event. Catalyst is focused on biopharmaceutical developments, particularly in rare hematologic disorders, with advanced clinical programs, including marzeptacog alfa and dalcinonacog alfa.

Catalyst Biosciences (NASDAQ: CBIO) announced participation in two investor conferences on September 17, 2020. The Morgan Stanley Global Healthcare Conference will feature CEO Nassim Usman and CFO Clinton Musil at 5:00 PM ET, with a webcast available. Concurrently, they will present at the Cantor Virtual Global Healthcare Conference at 4:40 PM ET, with a separate webcast.

Catalyst Biosciences (NASDAQ: CBIO) reported notable advancements and financial outcomes for Q2 2020, ending June 30, 2020. The company holds approximately $117 million in cash, supporting ongoing pipeline development, including pivotal Phase 3 trials of MarzAA for hemophilia. The quarterly net loss was $17.2 million, with a loss per share of $0.96, compared to a loss of $13.8 million and $1.15 per share in Q2 2019. R&D expenses increased by 16% to $12.9 million. Catalyst aims to initiate further trials and identify candidates in its gene therapy and complement programs by late 2020.

Catalyst Biosciences (NASDAQ: CBIO) presented data regarding marzeptacog alfa (activated) (MarzAA) at the ISTH Virtual Congress. The Phase 1 study showed that MarzAA quickly achieves therapeutic levels for treating acute bleeding in hemophilia patients. A Population PK model confirmed effective dosing for the upcoming Phase 3 trial, Crimson 1, set to start in late 2020. The results suggest a significant market opportunity for MarzAA, addressing a crucial need in bleeding disorder treatments.

Catalyst Biosciences (NASDAQ: CBIO) announced that Clinton Musil has been granted a non-qualified stock option to purchase 140,000 shares of common stock. This is part of his inducement package as the new Chief Financial Officer, effective July 1, 2020. The option has a ten-year term with an exercise price of $5.88 and will vest over four years. Catalyst focuses on developing treatments for rare hematologic conditions and has multiple clinical programs, including MarzAA, a next-generation treatment for hemophilia, set for a Phase 3 study in late 2020.